Literature DB >> 20369394

Anticancer drug development: the grand challenges.

William N Hait1.   

Abstract

Despite vast investment in oncology R&D, the translation of research advances into medicines that substantially improve the treatment of many cancers remains frustratingly slow. What are the key challenges in anticancer drug development, and how might they be addressed?

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20369394     DOI： 10.1038/nrd3144

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  64 in total

Review 1.  Hurdles in anticancer drug development from a regulatory perspective.

Authors:  Bertil Jonsson; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

2.  Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.

Authors:  Marnie Newell; Susan Goruk; Vera Mazurak; Lynne Postovit; Catherine J Field
Journal:  Breast Cancer Res Treat       Date:  2019-06-24       Impact factor: 4.872

3.  A transfection method of PS-asODNs targeting ANGPTL4 in multicellular structures of hepatocarcinoma cell line.

Authors:  Q Kong; G Wu; L Han; Z Zhang; J Du; W Sun; L Cao
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

4.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

Authors:  Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

Review 5.  Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.

Authors:  Hsin-Pei Shih; Xiaodan Zhang; Alex M Aronov
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

6.  High-Content Screening Comparison of Cancer Drug Accumulation and Distribution in Two-Dimensional and Three-Dimensional Culture Models of Head and Neck Cancer.

Authors:  Feng Shan; David A Close; Daniel P Camarco; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2017-12-07       Impact factor: 1.738

7.  Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor.

Authors:  Nenad L Ignjatović; Katarina M Penov-Gaši; Victoria M Wu; Jovana J Ajduković; Vesna V Kojić; Dana Vasiljević-Radović; Maja Kuzmanović; Vuk Uskoković; Dragan P Uskoković
Journal:  Colloids Surf B Biointerfaces       Date:  2016-09-28       Impact factor: 5.268

8.  Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Authors:  Magdalena Bieniasz; Parvathi Radhakrishnan; Najme Faham; Jean-Paul De La O; Alana L Welm
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

9.  Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.

Authors:  Meiyan Sun; Qunshu Zhang; Xiaoyu Yang; Steven Y Qian; Bin Guo
Journal:  Mol Cancer Ther       Date:  2016-07-25       Impact factor: 6.261

10.  New insights into ethionamide metabolism: influence of oxidized methionine on its degradation path.

Authors:  Nuno Vale; Diana Duarte; Alexandra Correia; Cláudia Alves; Patrícia Figueiredo; Hélder A Santos
Journal:  RSC Med Chem       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.